Financial Performance - Revenue for 2022 reached RMB 11,334,262 thousand, representing a 16.8% increase from RMB 9,703,438 thousand in 2021[12] - EBITDA for 2022 was RMB 2,640,792 thousand, up 40.2% from RMB 1,883,735 thousand in 2021[12] - Profit before tax increased by 66.9% to RMB 2,006,766 thousand compared to RMB 1,202,647 thousand in the previous year[12] - Net profit attributable to shareholders rose by 60.0% to RMB 1,581,094 thousand from RMB 988,098 thousand in 2021[12] - Basic earnings per share for 2022 were RMB 86.89, a 61.8% increase from RMB 53.70 in 2021[12] - The company declared a total dividend of RMB 25.0 per share for 2022, an increase of 78.6% from RMB 14.0 in 2021[12] - The total comprehensive income for the year amounted to RMB 1,582,450 thousand, compared to RMB 990,060 thousand in the previous year, showing robust overall performance[129] - The company reported a net profit of RMB 1,581,094 thousand for the year, compared to a profit of RMB 988,098 thousand in the previous year, showing an increase of 60%[135] Research and Development - Research and development investment reached RMB 593,600,000, an increase of 27.6% year-on-year, with significant progress in diabetes and ophthalmology drug development[21] - The company has 29 new products in development, including 15 first-class new drug projects, focusing on endocrine, autoimmune, and ophthalmology fields[33] - The company aims to continue expanding its market presence and investing in new product development to sustain growth momentum[130] Market and Business Development - The company plans to accelerate market development and commercialization processes, expanding external collaborations to diversify products and business[22] - The animal health business experienced rapid growth, benefiting from the implementation of new regulatory standards in the veterinary drug industry[23] - The company aims to leverage the opportunities presented by the transformation of the Chinese pharmaceutical industry to enhance its market position and influence[26] Financial Position - As of December 31, 2022, the company held cash and bank deposits of approximately RMB 5,437,800,000, an increase from RMB 4,158,400,000 in the previous year[37] - The group's current assets amounted to RMB 12,514,900,000, an increase from RMB 9,986,300,000 in 2021[38] - Total assets as of December 31, 2022, were approximately RMB 18,979,600,000, up from RMB 16,331,100,000 in 2021[38] - Total liabilities increased to approximately RMB 8,370,200,000 in 2022 from RMB 6,991,200,000 in 2021[38] - The equity attributable to owners rose from RMB 9,340,500,000 in 2021 to RMB 10,680,100,000 in 2022[38] Governance and Compliance - The company maintains compliance with applicable laws and regulations, with no significant violations reported for the year ending December 31, 2022[79] - The board consists of six executive directors and three independent non-executive directors, with a commitment to high corporate governance standards[84] - The company has a robust governance structure with independent non-executive directors overseeing audit, remuneration, and risk management committees[58][59] Shareholder Relations - The company emphasizes the importance of effective communication with shareholders to enhance investor relations and understanding of business performance and strategies[115] - The investor relations team, led by the Vice Chairman and the Director of Investor Relations, will continue to engage with investors through various platforms, including roadshows and conference calls[115] - The company aims to build a supportive shareholder base to enhance its market value[115] Financial Reporting and Audit - The financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards and reflect a true and fair view of the group's financial position as of December 31, 2022[117] - The audit report indicates that the financial statements are free from material misstatement due to fraud or error[118] - The auditor's fees for the year ended December 31, 2022, were approximately RMB 4,704,000 for audit services and RMB 1,603,000 for non-audit services[110] Employee and Management - The group employed approximately 14,000 staff as of December 31, 2022, compared to 13,300 in 2021, indicating growth in workforce[40] - The company has a strong management team with extensive experience in the pharmaceutical industry, including Mr. Wu Shou Ting, who has over 30 years of experience in production management[60] Legal and Regulatory Matters - The company has ongoing litigation to recover approximately RMB 340,000,000 from Chengdu Evergrande, with the case currently under review by the Chengdu Intermediate People's Court[42] - The company confirmed that there were no significant events that could question its ability to continue as a going concern as of December 31, 2022[110]
联邦制药(03933) - 2022 - 年度财报